-Advertisement-
-Advertisement-
Journal Scan
Lupus Nephritis

MMF reduces chronic damage progression in SLE

Posted on June 29, 2021
systemic lupus erythematosus

The immunosuppressive mycophenolate mofetil (MMF) is safe and effective in patients with systemic lupus erythematosus (SLE) manifestations other than lupus nephritis, according to a study.

In this longitudinal study, data from 162 patients with SLE prescribed MMF for LN (62.3%), musculoskeletal manifestations (24.1%), neuropsychiatric lupus (6.2%), and other manifestations (7.4%) were analyzed.

There was a median treatment duration of 30 months. In patients with LN, the 5-year drug retention rate was 61.1%, which the authors noted was similar to the rate seen in patients without renal involvement (60.5%).

Treatment with MMF was discontinued in 59.2% over the course of the observation period, with remission as the main cause of withdrawal (21.7%).

Reference
Olivieri G, Ceccarelli F, Natalucci F, et al. Five-years drug survival of mycophenolate mofetil therapy in patients with systemic lupus erythematosus: comparison between renal and non-renal involvement. Joint Bone Spine. 2021;105246. doi: 10.1016/j.jbspin.2021.105246. Epub ahead of print. PMID: 34171464.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-